AbbVie

AbbVie· Business · 7 sources · Sep 25, 2026Story

ADARx Raises $446 Million in Upsized IPO

ADARx Pharmaceuticals raised $446 million in an upsized IPO at $17 a share, the top of its range, and began Nasdaq trading under ADRX with an AbbVie private placement.

Business· Sep 25, 2026

0

AbbVie· Finance · 12 sources · Sep 21, 2026Story

ADARx Plans $350 Million IPO, AbbVie Stake

ADARx Pharmaceuticals plans a $350 million IPO by issuing 21.9 million shares at $15-$17 each, with AbbVie investing up to $100 million for about 4.9% of the company, valuing it around $1.8 billion and listing on Nasdaq as ADRX. The biotech focuses on siRNA therapies with three clinical-stage programs and two advanced preclinical programs, led by onvuzosiran in Phase 3 for hereditary angioedema, with pricing anticipated the week of September 21, 2026.

Finance· Sep 21, 2026

+3

AbbVie· Health · 12 sources · Sep 30, 2026Story

AbbVie’s Zumilokibart Hits EASI-75 Goal in Phase 2 Eczema Trial

At EADV 2026, long-term ADlong results showed sustained efficacy and safety with lebrikizumab through week 108, with 92.9% of participants achieving EASI-75. Separately, AbbVie’s Phase 2 trial found all zumilokibart doses beat placebo on the week-16 EASI-75 endpoint, and the mid-dose regimen was selected for Phase 3 development.

Health· Sep 30, 2026

0

AbbVie· Health · 9 sources · Sep 25, 2026Story

FDA approves AbbVie’s Juvmo for Parkinson’s

The FDA approved AbbVie’s once-daily oral drug Juvmo (tavapadon) for adults with Parkinson’s disease. Phase 3 trials found improvements in motor symptoms and daily function, adding another treatment option; common side effects included nausea, headache and dizziness.

Health· Sep 25, 2026

0

AbbVie

ADARx Raises $446 Million in Upsized IPO

ADARx Plans $350 Million IPO, AbbVie Stake

AbbVie’s Zumilokibart Hits EASI-75 Goal in Phase 2 Eczema Trial

FDA approves AbbVie’s Juvmo for Parkinson’s

AbbVie

ADARx Raises $446 Million in Upsized IPO

ADARx Plans $350 Million IPO, AbbVie Stake

AbbVie’s Zumilokibart Hits EASI-75 Goal in Phase 2 Eczema Trial

FDA approves AbbVie’s Juvmo for Parkinson’s

AbbVie across IJR

Miembros destacados

AbbVie across IJR

Últimas noticias y debate sobre AbbVie

ADARx Raises $446 Million in Upsized IPO

ADARx Plans $350 Million IPO, AbbVie Stake

AbbVie’s Zumilokibart Hits EASI-75 Goal in Phase 2 Eczema Trial

FDA approves AbbVie’s Juvmo for Parkinson’s

Últimas noticias y debate sobre AbbVie

ADARx Raises $446 Million in Upsized IPO

ADARx Plans $350 Million IPO, AbbVie Stake

AbbVie’s Zumilokibart Hits EASI-75 Goal in Phase 2 Eczema Trial

FDA approves AbbVie’s Juvmo for Parkinson’s

AbbVie across IJR

Miembros destacados

AbbVie across IJR